Neumora Therapeutics, Inc. Common Stock (NMRA) EBITDA Margin: History & Chart

Neumora Therapeutics, Inc. Common Stock(NMRA)

Biotechnology · Watertown, MA

$0.49-0.04 (-7.39%)

Delayed quote: Oct 6, 2026, 12:45 PM EDT

About Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Watertown, MA

63 employees

www.neumoratx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Josh Pinto

View full financials

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Neumora Therapeutics, Inc. Common Stock (NMRA)	$90.14M	N/A	N/A	N/A	N/A
PMV Pharmaceuticals, Inc. (PMVP)vs ›	$89.06M	N/A	N/A	N/A	N/A
electroCore, Inc. (ECOR)vs ›	$90.16M	-35.83%	-39.56%	-111.97%	-250.85%
Rallybio Corporation (RLYB)vs ›	$90.32M	-3260.14%	-6375.74%	-6375.74%	-6375.74%
ImmuCell Corporation (ICCC)vs ›	$88.48M	15.84%	9.89%	0.86%	4.00%
Equillium, Inc. (EQ)vs ›	$90.73M	-19.79%	-29.84%	-150.95%	-150.95%
Biomea Fusion, Inc. (BMEA)vs ›	$92.54M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$85.33M	31.45%	-14.67%	-906.21%	-1050.55%
CareCloud, Inc. (CCLD)vs ›	$86.90M	23.63%	23.21%	8.97%	9.09%
Park Dental Partners, Inc. Common Stock (PARK)vs ›	$93.26M	5.05%	6.33%	5.80%	5.80%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Neumora Therapeutics, Inc. Common Stock (NMRA)

$90.14M

N/A

PMV Pharmaceuticals, Inc. (PMVP)vs ›

$89.06M

N/A

electroCore, Inc. (ECOR)vs ›

$90.16M